Literature DB >> 18771438

Identification of the most active interleukin-32 isoform.

Ji-Da Choi1, Su-Young Bae, Jae-Woo Hong, Tania Azam, Charles A Dinarello, Erk Her, Whan-Soo Choi, Bo-Kyung Kim, Chang-Kwon Lee, Do-Young Yoon, Sun-Jong Kim, Soo-Hyun Kim.   

Abstract

Cytokines are crucial in host defence against pathogens such as bacteria, viruses, fungi and parasites. A newly described cytokine, interleukin-32 (IL-32), induces various proinflammatory cytokines (tumour necrosis factor-alpha, IL-1beta, IL-6) and chemokines in both human and mouse cells through the nuclear factor-kappaB and p38 mitogen-activated protein kinase inflammatory signal pathway. The IL-32 primarily acts on monocytic cells rather than T cells. In an attempt to isolate the IL-32 soluble receptor, we used an IL-32 ligand-affinity column to purify neutrophil proteinase 3, which is a serine proteinase involved in many inflammatory diseases. IL-32 has biological activity associated with Mycobacterium tuberculosis and chronic proinflammatory diseases such as rheumatoid arthritis. IL-32 is transcribed as six alternative splice variants and the biological activity of each individual isoform remains unknown. Here, we cloned the complementary DNA of the four IL-32 isoforms (alpha, beta, gamma and delta) that are the most representative IL-32 transcripts. To produce recombinant protein with a high yield, the amino acids of two cysteine residues were mutated to serine residues, because serine residues are not conserved among different species. The multi-step purified recombinant IL-32 isoform proteins were assessed for their biological activities with different cytokine assays. The gamma isoform of IL-32 was the most active, although all isoforms were biologically active. The present study will provide a specific target to neutralize endogenous IL-32, which may contribute to basic and clinical immunology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18771438      PMCID: PMC2673365          DOI: 10.1111/j.1365-2567.2008.02917.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

1.  Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract.

Authors:  Koichi S Kobayashi; Mathias Chamaillard; Yasunori Ogura; Octavian Henegariu; Naohiro Inohara; Gabriel Nuñez; Richard A Flavell
Journal:  Science       Date:  2005-02-04       Impact factor: 47.728

Review 2.  Immune functions of proteinase 3.

Authors:  Shunji Sugawara
Journal:  Crit Rev Immunol       Date:  2005       Impact factor: 2.214

3.  Involvement of IL-32 in activation-induced cell death in T cells.

Authors:  Chiho Goda; Taisuke Kanaji; Sachiko Kanaji; Go Tanaka; Kazuhiko Arima; Shigeaki Ohno; Kenji Izuhara
Journal:  Int Immunol       Date:  2006-01-12       Impact factor: 4.823

Review 4.  Infliximab for the treatment of early rheumatoid arthritis.

Authors:  Robin C Geletka; E William St Clair
Journal:  Expert Opin Biol Ther       Date:  2005-03       Impact factor: 4.388

5.  IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism.

Authors:  Mihai G Netea; Tania Azam; Gerben Ferwerda; Stephen E Girardin; Mark Walsh; Jong-Sung Park; Edward Abraham; Jin-Man Kim; Do-Young Yoon; Charles A Dinarello; Soo-Hyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-31       Impact factor: 11.205

Review 6.  Interleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions.

Authors:  Michele Bombardieri; Iain B McInnes; Costantino Pitzalis
Journal:  Expert Opin Biol Ther       Date:  2007-01       Impact factor: 4.388

7.  Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines.

Authors:  R Meazza; S Verdiani; R Biassoni; M Coppolecchia; A Gaggero; A M Orengo; M P Colombo; B Azzarone; S Ferrini
Journal:  Oncogene       Date:  1996-05-16       Impact factor: 9.867

8.  Proteinase 3 is an IL-32 binding protein.

Authors:  Daniela Novick; Menachem Rubinstein; Tania Azam; Aharon Rabinkov; Charles A Dinarello; Soo-Hyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-17       Impact factor: 11.205

9.  IL-32, a proinflammatory cytokine in rheumatoid arthritis.

Authors:  Leo A B Joosten; Mihai G Netea; Soo-Hyun Kim; Do-Young Yoon; Birgitte Oppers-Walgreen; Timothy R D Radstake; Pilar Barrera; Fons A J van de Loo; Charles A Dinarello; Wim B van den Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

Review 10.  TNF, apoptosis and autoimmunity: a common thread?

Authors:  B Beutler; F Bazzoni
Journal:  Blood Cells Mol Dis       Date:  1998-06       Impact factor: 3.039

View more
  71 in total

1.  Paradoxical effects of constitutive human IL-32{gamma} in transgenic mice during experimental colitis.

Authors:  Jida Choi; Suyoung Bae; Jaewoo Hong; Soyoon Ryoo; Hyunjhung Jhun; Kwangwon Hong; Doyoung Yoon; Siyoung Lee; Erk Her; Wonhyuk Choi; Jeonghwan Kim; Tania Azam; Charles A Dinarello; Soohyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

2.  The influence of interleukin-32γ on osteoclastogenesis with a focus on fusion-related genes.

Authors:  Yong-Gil Kim; Min Wook So; Bon San Koo; Eun-Ju Chang; Seok Jong Song; Chang-Keun Lee; Bin Yoo
Journal:  J Clin Immunol       Date:  2011-11-09       Impact factor: 8.317

3.  Significant association between IL-32 gene polymorphisms and susceptibility to endometrial cancer in Chinese Han women.

Authors:  Xiuzhang Yu; Bin Zhou; Zhu Zhang; Qianqian Gao; Yanyun Wang; Yaping Song; Yan Pu; Yue Chen; Ruiqi Duan; Lin Zhang; Mingrong Xi
Journal:  Tumour Biol       Date:  2015-02-09

4.  Interleukin-32gamma enhances the production of IL-6 and IL-8 in fibroblast-like synoviocytes via Erk1/2 activation.

Authors:  Yong-Gil Kim; Chang-Keun Lee; Soo-Hyun Kim; Woo-Shin Cho; Se Hwan Mun; Bin Yoo
Journal:  J Clin Immunol       Date:  2010-01-14       Impact factor: 8.317

5.  The inhibitory function of Fc-ST2 depends on cell type; IL-1RAcP and ST2 are necessary but insufficient for IL-33 activity.

Authors:  Kwangwon Hong; Youngmin Lee; Siyoung Lee; Sungnoh Hong; Suyoung Bae; Jaewoo Hong; Jida Choi; Hyunjhung Jhun; Areum Kwak; Eunsom Kim; Seunghyun Jo; Taebong Kang; You Sook Cho; Yong-Gil Kim; Soohyun Kim
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

6.  Dendritic Cell-Derived IL-32α: A Novel Inhibitory Cytokine of NK Cell Function.

Authors:  Laurent Gorvel; Daniel Korenfeld; Thomas Tung; Eynav Klechevsky
Journal:  J Immunol       Date:  2017-07-12       Impact factor: 5.422

7.  Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.

Authors:  Janis M Taube; Geoffrey D Young; Tracee L McMiller; Shuming Chen; January T Salas; Theresa S Pritchard; Haiying Xu; Alan K Meeker; Jinshui Fan; Chris Cheadle; Alan E Berger; Drew M Pardoll; Suzanne L Topalian
Journal:  Clin Cancer Res       Date:  2015-05-05       Impact factor: 12.531

Review 8.  IL-32θ: a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity.

Authors:  Muhammad Babar Khawar; Maryam Mukhtar; Muddasir Hassan Abbasi; Nadeem Sheikh
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

9.  Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients.

Authors:  Katia Monteleone; Pierluigi Di Maio; Giulia Cacciotti; Francesca Falasca; Maurizio Fraulo; Mario Falciano; Ivano Mezzaroma; Gabriella D'Ettorre; Ombretta Turriziani; Carolina Scagnolari
Journal:  Med Microbiol Immunol       Date:  2014-02-20       Impact factor: 3.402

10.  Innate immunity triggers IL-32 expression by fibroblast-like synoviocytes in rheumatoid arthritis.

Authors:  Ghada Alsaleh; Laetitia Sparsa; Emmanuel Chatelus; Mathieu Ehlinger; Jacques-Eric Gottenberg; Dominique Wachsmann; Jean Sibilia
Journal:  Arthritis Res Ther       Date:  2010-07-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.